Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with or without tifcemalimab as consolidation after chemoradiotherapy for limited-stage small cell lung cancer
NL-OMON60017Phase 3Active, not recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Tifcemalimab + toripalimab, Toripalimab and Placebo (3 arms). Primary endpoints: Overall survival and Blinded Independent Review Committee-assessed progression-free survival. Started Mar 2025; status: active, not recruiting.
02
Drugs
toripalimabtifcemalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON60017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60017.